Headache

Article	Citations
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	372
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys	146
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study	77
Hypertension: A new safety risk for patients treated with erenumab	68
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study	67
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2	63
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study	58
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency	55
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	46
Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review	46
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial	46
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study	45
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study	45
Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management	45
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios	44
Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire	42
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	41
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1	40
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial	37
Remote electrical neuromodulation for acute treatment of migraine in adolescents	36
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation	36
A link between gastrointestinal disorders and migraine: Insights into the gut–brain connection	35
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing	35
Systematic review of outcomes and endpoints in preventive migraine clinical trials	35
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data	34

Spontaneous spinal cerebrospinal fluid‐venous fistulas in patients with orthostatic headaches and normal conventional brain and spine imaging	33
Learning the full impact of migraine through patient voices: A qualitative study	33
Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction	33
Smartphone‐Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial	30
Patient experience of telemedicine for headache care during the COVID‐19 pandemic: An American Migraine Foundation survey study	29
Systematic review of outcomes and endpoints in acute migraine clinical trials	29
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study	29
Trigeminal neuralgia as the sole neurological manifestation of COVID‐19: A case report	29
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial	29
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patien	28
Cyclic vomiting syndrome: A narrative review and guide to management	28
Real‐world efficacy, tolerability, and safety of ubrogepant	28
Management of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review	27
Dietary magnesium and migraine in adults: A cross‐sectional analysis of the National Health and Nutrition Examination Survey 2001–2004	27
Headache in transgender and gender‐diverse patients: A narrative review	27
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache	26
Headache education by leaflet distribution during COVID‐19 vaccination and school‐based on‐demand e‐learning: Itoigawa Geopark Headache Awareness Campaign	24
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome	24
Indomethacin‐responsive headaches—A narrative review	24
Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients	23
Serum lipid abnormalities in migraine: A meta‐analysis of observational studies	23
63rd Annual Scientific Meeting American Headache Society®	23
Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review	23
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi‐center study	23
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial	21
The changing face of trigeminal neuralgia—A narrative review	21
Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study	21
Alterations in the structure and function of the brain in adolescents with new daily persistent headache: A pilot MRI study	20
Prevalence and association of lifestyle and medical‐, psychiatric‐, and pain‐related comorbidities in patients with migraine: A cross‐sectional study	20
Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation	19
Dietary zinc intake and migraine in adults: a cross‐sectional analysis of the National Health and Nutrition Examination Survey 1999–2004	19
Prolactin signaling modulates stress‐induced behavioral responses in a preclinical mouse model of migraine	19
Headache response after CT‐guided fibrin glue occlusion of CSF‐venous fistulas	18
Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update	18
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine	18
Green Flags and headache: A concept study using the Delphi method	18
Telehealth as a new care delivery model: The headache provider experience	18
Early impact of the COVID‐19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey	18
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis	17
Psychometric validation and meaningful within‐patient change of the Migraine‐Specific Quality of Life questionnaire version 2.1 electronic patient‐reported outcome in patients with episodic and chroni	17
Normal glymphatic system function in patients with migraine: A pilot study	17
Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine	17
Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)—A multinational observational study	17
The unique role of stigma in migraine‐related disability and quality of life	17
Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross‐sectional study	17
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	16
Evidence that blood–CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen	16
Telehealth perceptions and utilization for the delivery of headache care before and during the COVID‐19 pandemic: A mixed‐methods study	16
Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six‐week prospective cohort study of patients with episodic migraine	16
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acu	16

The intersection of COVID‐19, school, and headaches: Problems and solutions	16
Impact of abuse on migraine‐related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research	15
Migraine and light: A narrative review	15
Primary headaches among gender dysphoric female‐to‐male individuals: A cross‐sectional survey on gender transition experience	15
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men	15
Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire	15
A non‐convulsant delta‐opioid receptor agonist, KNT‐127, reduces cortical spreading depression and nitroglycerin‐induced allodynia	15
Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross‐sectional survey	15
Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data	15
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study	15
The endocannabinoid system and related lipids as potential targets for the treatment of migraine‐related pain	14
Clinical features of new daily persistent headache: A retrospective chart review of 328 cases	14
Measurement properties of the Headache Impact Test (HIT‐6™ Brazil) in primary and secondary headaches	14
Characteristics and natural disease history of persistent idiopathic facial pain, trigeminal neuralgia, and neuropathic facial pain	14
The relationship of headache as a symptom to COVID‐19 survival: A systematic review and meta‐analysis of survival of 43,169 inpatients with COVID‐19	14
Migraine diagnosis and treatment: A knowledge and needs assessment of women’s healthcare providers	14
Erenumab patient characteristics, medication adherence, and treatment patterns in the United States	14
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond	14
Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States	14
Arachnoiditis, a complication of epidural blood patch for the treatment of low‐pressure headache: A case report and systematic review	13
Association among headache, temporomandibular disorder, and awake bruxism: A cross‐sectional study	13
Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial	13
Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine	13
A real‐world, observational study of erenumab for migraine prevention in Canadian patients	13
Allodynia and Disability in Migraine: The Mediating Role of Stress	13
Migraine and Sport in a Physically Active Population of Students: Results of a Cross‐Sectional Study	13
American Headache Society 64th Annual Scientific Meeting June 9–12, 2022 Denver, Colorado	13
Cluster headache pathophysiology: What we have learned from advanced neuroimaging	13
Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine	13
A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management	12
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment	12
Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study	12
Headache as a COVID‐19 onset symptom and post‐COVID‐19 symptom in hospitalized COVID‐19 survivors infected with the Wuhan, Alpha, or Delta SARS‐CoV‐2 varian	12
The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic mi	12
Impact of the COVID‐19 pandemic on people living with migraine: Results of the MiCOAS qualitative study	12
Aura phenomena do not initiate migraine attacks—Findings from neuroimaging	12
An observational study of self‐reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App)	12
The current state of headache medicine education in the United States and Canada: An observational, survey‐based study of neurology clerkship directors and curriculum deans	12
The role of artificial intelligence in headache medicine: Potential and peril	12
Narrative review of peripheral nerve blocks for the management of headache	12
Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary	12
Validity and reliability of the self‐administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic‐based study	12
Sex differences in migraine attack characteristics: A longitudinal E‐diary study	12
A new hypothesis linking oxytocin to menstrual migraine	12
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review	12
Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review	11
Effectiveness of manual therapy in the treatment of cervicogenic headache: A systematic review	11
The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015‐2016	11
The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review	11
Wildfire smoke exposure and emergency department visits for headache: A case‐crossover analysis in California, 2006–2020	11
Are psychological interventions efficacious for adults with migraine? A systematic review and meta‐analysis	11
Headache and systemic lupus erythematosus: A narrative review	11
Developing an artificial intelligence–based diagnostic model of headaches from a dataset of clinic patients' records	11
A causative role for remote dural puncture and resultant arachnoid bleb in new daily persistent headache: A case report	11
Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study	11
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study	11
Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine	10
Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study	10
Trigeminal neuralgia in children and adolescents: Experience of a tertiary pediatric headache clinic	10
Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial	10
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity	10
Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial	10
“You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey	10
Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English‐speaking countries	10
Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials	10
Migraine and peripheral pain models show differential alterations in neuronal complexity	10
Regional cerebral perfusion during the premonitory phase of triggered migraine: A double‐blind randomized placebo‐controlled functional imaging study using pseudo‐continuous arterial spin labeling	10
Introducing Headache’s “Trainee Highlights”	9
Shared biological foundations of post‐traumatic headache and migraine	9
Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies	9
Headache Due to COVID‐19: A Disabling Combination	9
Gene polymorphism association studies in cluster headache: A field synopsis and systematic meta‐analyses	9
Popping the balloon: Abrupt onset of a spinal CSF leak and spontaneous intracranial hypotension in idiopathic intracranial hypertension, a case report	9
Acute and chronic management of posttraumatic headache in children: A systematic review	9
Migraine treatment and COVID‐19 vaccines: No cause for concern	9
Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors	9
Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report	9
Equity of African American Men in Headache in the United States: A Perspective From African American Headache Medicine Specialists (Part 2)	9
Did she have an epidural? The long‐term consequences of postdural puncture headache and the role of unintended dural puncture	9
Equity of African American Men in Headache in the United States: A Perspective From African American Headache Medicine Specialists (Part 1)	9

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) ant	9
Ten Eleven things to facilitate participation of underrepresented groups in headache medicine research	9
Different characteristics of cortical spreading depression in the sleep and wake states	9
Structural aberrations of the brain associated with migraine: A narrative review	9
Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes	9
A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine	8
Timing and durability of response to erenumab in patients with episodic migraine	8
Medication overuse headache in patients with chronic migraine using cannabis: A case–referent study	8
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes	8
Impact of emergency department opioid use on future health resource utilization among patients with migraine	8
A prospective, randomized, double‐blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department	8
Later high school start time is associated with lower migraine frequency in adolescents	8
Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention	8
Patient preference for early onset of efficacy of preventive migraine treatments	8
Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE‐2 trial	8
Primary headache disorders and body mass index categories: A systematic review and dose–response meta‐analysis	8
Treatment of medication overuse headache: Effect and predictors after 1 year—A randomized controlled trial	8
Postural control impairment in patients with headaches—A systematic review and meta‐analysis	8
Cancer risk in patients with migraine: A population‐based cohort study in Denmark	8
Association between secondhand smoke exposure and severe headaches or migraine in never‐smoking adults	8
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine	8
Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity	8
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review	8
Role of memantine in the prophylactic treatment of episodic migraine: A systematic review	7
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real‐life perspective from the Italian chROnic migraiNe (IRON) pro	7
A pain in the ear: Two case reports of nervus intermedius neuralgia and narrative review	7
Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension‐type headache enrolled in commercial insurance plans	7
Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: A matched controlled cohort study	7
Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors	7
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space	7
Migraine and large artery atherosclerosis in young adults with ischemic stroke	7
Raynaud's phenomenon associated with calcitonin gene‐related peptide receptor antagonists case report	7
Prolactin in headache and migraine: A systematic review of preclinical studies	7
	7
Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative study	7
Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor ant	7
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache	7
Treatment of multiple sclerosis–related trigeminal neuralgia with onabotulinumtoxinA	7
Clinical characteristics of medication‐overuse headache according to the class of acute medication: A cross‐sectional multicenter study	7
Paradoxical headache in a case of chronic spontaneous intracranial hypotension and multiple perineural cysts	7
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo‐controlled study	7
The Headache in Emergency Departments study: Opioid prescribing in patients presenting with headache. A multicenter, cross‐sectional, observational study	7
Skin wetness sensitivity across body sites commonly affected by pain in people with migraine	7
Spatial aspects of pain modulation are not disrupted in adolescents with migraine	7
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data	6
Increasing and disparate use of neuroimaging for adults and children with non‐traumatic headaches in the US emergency departments: Opportunities for improvement	6
Clinical characteristics and perfusion‐computed tomography alterations in a series of patients with migraine with aura attended as stroke code	6
Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review	6
Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia	6
The effect of needle size on cerebrospinal fluid collection time and post‐dural puncture headache: A retrospective cohort study	6
A stated preference survey to explore patient preferences for novel preventive migraine treatments	6
Etoricoxib and celecoxib sensitive indomethacin‐responsive headache disorders	6
Management and outcomes of persistent headache after accidental dural puncture in the obstetric population: A 9‐year prospective audit	6
Protracted headache after COVID‐19: A case series of 31 patients from a tertiary headache center	6
Aryl hydrocarbon receptors improve migraine‐like pain behaviors in rats through the regulation of regulatory T cell/T‐helper 17 cell‐related homeostasis	6
Effects of caffeine on intracranial pressure and pain perception in freely moving rats	6
Continuous updating of individual headache forecasting models using Bayesian methods	6
Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil) cohort: A cross‐sectional study	6
Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases	6
Feasibility of using “SMARTER” methodology for monitoring precipitating conditions of pediatric migraine episodes	6
Developmental innervation of cranial dura mater and migraine headache: A narrative literature review	6
Timing and durability of response to erenumab in patients with chronic migraine	6
Network meta‐analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster	6
The migraine signature study: Methods and baseline results	6
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid	6
Developing multivariable models for predicting headache improvement in patients with acute post‐traumatic headache attributed to mild traumatic brain injury: A preliminary study	6
Beyond pain control: Outcome and treatment preferences in pediatric migraine	6
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine	6
Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine	6
Quantitative arterial spin labeling magnetic resonance imaging analysis of reversible cerebral vasoconstriction syndrome: A case series	6
Headache during COVID‐19: Lessons for all, implications for the International Classification of Headache Disorders	6